Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-494 open-label extension in rheumatoid arthritis
NL-OMON41802Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of upadacitinib in rheumatoid arthritis (RA), sponsored by AbbVie Inc. Planned start May 2014; status: withdrawn.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41802.